Purpose, development, and limitations of Antipsychotics and their Side Effects   pp. xviii-xix

Purpose, development, and limitations of <i>Antipsychotics and their Side Effects</i>

By David M. Gardner, Michael D. Teehan and Ross Baldessarini

Image View Previous Chapter Next Chapter



Purpose

The possible side effects of antipsychotics are extensive, varied, frequently intolerable, too often serious, and sometimes fatal. Clinicians cannot be expected to use these drugs optimally in the care of their patients when inexperienced with the antipsychotic prescribed or unfamiliar with the adverse possibilities and how to monitor for them. This book aims to support clinicians in improving the safe, long-term use of antipsychotic drugs by their patients. Specifically, this book is designed to (1) help inform antipsychotic treatment selections for individual patients (Section 1); and (2) support monitoring of antipsychotic-related side effects over the course of therapy (Sections 2 … 3). For more details, refer to the Guide to using Antipsychotics and their Side Effects on p. xx.

Antipsychotics and Their Side Effects was developed as a comprehensive, extensively referenced resource following a semi-systematic approach using three main sources of information: (1) the best available evidence; (2) identification of best practices; and (3) incorporation of our clinical and expert opinion.

Development

There is little or no research that directly assesses the best methods for the monitoring of antipsychotic treatment tolerance or safety. However, selected research and information on the effectiveness, tolerability, and safety of antipsychotics can be used to develop appropriate monitoring practices.

Reference Title: References

Reference Type: reference-list

Baldessarini RJ , Tarazi FI . Pharmacotherapy of psychosis and mania. In Brunton LL , Lazo JS , Parker K , eds., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn. New York: McGraw-Hill; 2006.
Lambert PA . Chlorpromazine: a true story of the progress effected by this drug. In Ban TA , Healy D , Shorter E , eds., The Rise of Psychopharmacology and the Story of CINP. Budapest: Animula; 1998.
Swazey JP . Chlorpromazine in Psychiatry: a Study in Therapeutic Innovation. Cambridge, MA: MIT Press; 1974.
Anonymous . Hazards of chlorpromazine. Br Med J 1956;1(4963):391–2.
Winkelman NW, Jr. Chlorpromazine in the treatment of neuropsychiatric disorders. J Am Med Assoc 1954;155(1):18–21.
Tasker JR Fatal agranulocytosis during treatment with chlorpromazine. Br Med J 1955;1(4919):950–1.
Bockner S . Neurological symptoms with phenothiazines. Br Med J 1964;2(5413):876.
Freyhan FA . Psychomotility and parkinsonism in treatment with neuroleptic drugs. AMA Arch Neurol Psychiatry 1957;78(5):465–72.
Simpson GM , Angus JW . A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11–19.
Guy W . ECDEU Assessment Manual for Psychopharmacology. Rev. edn. Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
Ayd FJ, Jr . Chlorpromazine: ten years' experience. JAMA 1963;184:51–4.
Baldessarini RJ , Frankenburg FR . Clozapine. A novel antipsychotic agent. N Engl J Med 1991;324(11):746–54.
Meltzer HY , Matsubara S , Lee JC . The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989;25(3):390–2.
Kapur S , Seeman P . Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001;158(3):360–9.
Seeman P . Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47(1):27–38.
Seeman P . An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry 2005;162(10):1984–5.
Shapiro DA , Renock S , Arrington E , et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28(8):1400–11.
DeLeon A , Patel NC , Crismon ML . Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004;26(5):649–66.
Domino ME , Swartz MS . Who are the new users of antipsychotic medications? Psychiatr Serv 2008;59(5):507–14.
Olfson M , Blanco C , Liu L , Moreno C , Laje G . National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006;63(6):679–85.
Mohamed S , Leslie DL , Rosenheck RA . Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs. J Clin Psychiatry 2009;70(6):906–12.
Kamble P , Chen H , Sherer J , Aparasu RR . Antipsychotic drug use among elderly nursing home residents in the United States. Am J Geriatr Pharmacother 2008;6(4):187–97.
IMS Health Incorporated . Top-line industry data: 2008 U.S. sales and prescription information. Top therapeutic classes by U.S. sales. 2008 (cited August 11, 2009). Available from: www.imshealth.com.
Gardner DM , Baldessarini RJ , Waraich P . Modern antipsychotic drugs: a critical overview. CMAJ 2005;172(13):1703–11.
Newcomer JW , Hennekens CH . Severe mental illness and risk of cardiovascular disease. JAMA 2007;298(15):1794–6.
Harris EC , Barraclough B . Excess mortality of mental disorder. Br J Psychiatry 1998;173:11–53.
Osby U , Correia N , Brandt L , Ekbom A , Sparen P . Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45(1–2):21–8.
Osby U , Brandt L , Correia N , Ekbom A , Sparen P . Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001;58(9):844–50.
Curkendall SM , Mo J , Glasser DB , Rose Stang M , Jones JK . Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry 2004;65(5):715–20.
Newcomer JW . Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry 2006;67 Suppl. 9:25–30; discussion 36–42.
Brown S . Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997;171:502–8.
Fontaine KR , Heo M , Harrigan EP , et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 2001;101(3):277–88.
Casey DE , Haupt DW , Newcomer JW , et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004;65 Suppl. 7:4–18.
Newcomer JW . Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses. J Clin Psychiatry 2009;70 Suppl. 3:30–6.
Ray WA , Chung CP , Murray KT , Hall K , Stein CM . Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360(3):225–35.
Singh S , Wooltorton E . Increased mortality among elderly patients with dementia using atypical antipsychotics. CMAJ 2005;173(3):252.
US Food and Drug Administration . Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. May 7, 2009 (cited August 27, 2009). Available from: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm053171.htm.
Wang PS , Schneeweiss S , Avorn J , et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353(22):2335–41.
Schneeweiss S , Setoguchi S , Brookhart A , Dormuth C , Wang PS . Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007;176(5):627–32.
Gill SS , Bronskill SE , Normand SL , et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007;146(11):775–86.
Yan J . FDA extends black-box warning to all antipsychotics. Psychiatr News 2008;43(14):1.
Fleischhacker WW , Cetkovich-Bakmas M , De Hert M , et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 2008;69(4):514–19.
Fagiolini A , Goracci A . The effects of undertreated chronic medical illnesses in patients with severe mental disorders. J Clin Psychiatry 2009;70 Suppl. 3:22–9.
Frayne SM , Halanych JH , Miller DR , et al. Disparities in diabetes care: impact of mental illness. Arch Intern Med 2005;165(22):2631–8.
Druss BG , Bradford DW , Rosenheck RA , Radford MJ , Krumholz HM . Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA 2000;283(4):506–11.
Druss BG , Bradford WD , Rosenheck RA , Radford MJ , Krumholz HM . Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 2001;58(6):565–72.
Druss BG , Rosenheck RA , Desai MM , Perlin JB . Quality of preventive medical care for patients with mental disorders. Med Care 2002;40(2):129–36.
Kisely S , Smith M , Lawrence D , Cox M , Campbell LA , Maaten S . Inequitable access for mentally ill patients to some medically necessary procedures. CMAJ 2007;176(6):779–84.
Jennex A , Gardner DM . Monitoring and management of metabolic risk factors in outpatients taking antipsychotic drugs: a controlled study. Can J Psychiatry 2008;53(1):34–42.
Bergersen BM , Sandvik L , Bruun JN , Tonstad S . Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004;23(8):625–30.
Morrato EH , Newcomer JW , Kamat S , Baser O , Harnett J , Cuffel B . Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 2009;32(6):1037–42.
Himelhoch S , Leith J , Goldberg R , Kreyenbuhl J , Medoff D , Dixon L . Care and management of cardiovascular risk factors among individuals with schizophrenia and type 2 diabetes who smoke. Gen Hosp Psychiatry 2009;31(1):30–2.
Kreyenbuhl J , Medoff DR , Seliger SL , Dixon LB . Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and type 2 diabetes. Schizophr Res 2008;101(1–3):256–65.
Lambert TJ , Newcomer JW . Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Med J Aust 2009;190(4 Suppl.):S39–42.
Lieberman JA , Stroup TS , McEvoy JP , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209–23.
Jones PB , Barnes TR , Davies L , et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63(10):1079–87.
Leucht S , Corves C , Arbter D , Engel RR , Li C , Davis JM . Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31–41.
Lewis S , Lieberman J . CATIE and CUtLASS: can we handle the truth? Br J Psychiatry 2008;192(3):161–3.
Dukes MNG . Side effects of drugs essay: the moments of truth. In Dukes MNG , ed., Side Effects of Drugs Annual, 1st edn. Amsterdam: Excerpta Medica; 1977.
Tyrer P , Kendall T . The spurious advance of antipsychotic drug therapy. Lancet 2009;373(9657):4–5.
Parks J , Radke A , Parker G , et al. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull 2009;35(5):931–6.
Chouinard G , Ross-Chouinard A , Annable L , Jones B . The extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7(3):233.
Lingjaerde O , Ahlfors UG , Bech P , Dencker SJ , Elgen K . The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1–100.
Marder SR , Essock SM , Miller AL , et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161(8):1334–49.
Feeney L , Mooney M . Atypical antipsychotic monitoring in the Kilkenny mental health services. Ir J Psychol Med 2005;22(3):101–2.
Olson KL , Delate T , Duagn DJ . Monitoring of patients given second-generation antipsychotic agents. Psychiatr Serv 2006;57(7):1045–6.
Nguyen D , Brakoulias V , Boyce P . An evaluation of monitoring practices in patients on second generation antipsychotics. Australas Psychiatry 2009;17(4):295–9.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity . Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27(2):596–601.
Druss BG . Improving medical care for persons with serious mental illness: challenges and solutions. J Clin Psychiatry 2007;68 Suppl. 4:40–4.
Committee on Crossing the Quality Chasm: Adaptation to Mental Health and Addictive Disorders, Institute of Medicine, Board on Health Care Services . Improving the Quality of Health Care for Mental and Substance-use Conditions. Washington, DC: The National Academic Press; 2006.
Druss BG , von Esenwein SA . Improving general medical care for persons with mental and addictive disorders: systematic review. Gen Hosp Psychiatry 2006;28(2):145–53.
Druss BG , Rohrbaugh RM , Levinson CM , Rosenheck RA . Integrated medical care for patients with serious psychiatric illness: a randomized trial. Arch Gen Psychiatry 2001;58(9):861–8.
Goff DC , Cather C , Evins AE , et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 2005;66(2):183–94.
Murphy AL , Gardner DM , Kutcher S , Davidson S , Manion I . Collaborating with youth to inform and develop tools for psychotropic decision making. J Can Acad Child Adolesc Psychiatry 2010 (in press).
Kane JM . Creating a health care team to manage chronic medical illnesses in patients with severe mental illness: the public policy perspective. J Clin Psychiatry 2009;70 Suppl. 3:37–42.

Reference Title: References

Reference Type: reference-list

Baldessarini RJ , Tarazi FI . Pharmacotherapy of psychosis and mania. In Brunton LL , Lazo JS , Parker K , eds., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn. New York: McGraw-Hill; 2006.
Bristol-Myers Squibb , Otsuka America Pharmaceutical . Abilify (Aripiprazole) U.S. Full Prescribing Information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd.; 2008.
Qureshi SU , Rubin E . Risperidone- and aripiprazole-induced leukopenia: a case report. Prim Care Companion J Clin Psychiatry 2008;10(6):482–3.
Mendhekar D , Duggal H , Andrade C . Leukopenia and thrombocytopenia on adding aripiprazole to phenytoin. World J Biol Psychiatry 2008;7:1–2.
Novartis Pharmaceuticals Canada Inc . Clozaril (Clozapine) Canadian Prescribing Information. Dorval, QC: Novartis Pharmaceuticals Canada Inc.; 2007.
Alvir JM , Lieberman JA , Safferman AZ , Schwimmer JL , Schaaf JA . Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329(3):162–7.
Iqbal MM , Rahman A , Husain Z , Mahmud SZ , Ryan WG , Feldman JM . Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 2003;15(1):33–48.
Collaborative Working Group on Clinical Trial Evaluations . Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998;59 Suppl. 12:17–22.
Pisciotta V . Drug-induced agranulocytosis. Drugs 1978;15(2):132–43.
Alphs LD , Anand R . Clozapine: the commitment to patient safety. J Clin Psychiatry 1999;60 Suppl. 12:39–42.
Patel NC , Dorson PG , Bettinger TL . Sudden late onset of clozapine-induced agranulocytosis. Ann Pharmacother 2002;36(6):1012–15.
Barbui C , Campomori A , Bonati M . Clozapine and blood dyscrasias different from agranulocytosis. Can J Psychiatry 1997;42(9):981–2.
Tolosa-Vilella C , Ruiz-Ripoll A , Mari-Alfonso B , Naval-Sendra E . Olanzapine-induced agranulocytosis: a case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry 2002;26(2):411–14.
Naumann R , Felber W , Heilemann H , Reuster T . Olanzapine-induced agranulocytosis. Lancet 1999;354(9178):566–7.
Stergiou V , Bozikas VP , Garyfallos G , Nikolaidis N , Lavrentiadis G , Fokas K . Olanzapine-induced leucopenia and neutropenia. Prog Neuropsychopharmacol Biol Psychiatry 2005;29(6):992–4.
Duggal HS , Gates C , Pathak PC . Olanzapine-induced neutropenia: mechanism and treatment. J Clin Psychopharmacol 2004;24(2):234–5.
Benedetti F , Cavallaro R , Smeraldi E . Olanzapine-induced neutropenia after clozapine-induced neutropenia. Lancet 1999;354(9178):567.
Gajwani P , Tesar GE . Olanzapine-induced neutropenia. Psychosomatics 2000;41(2):150–1.
Kodesh A , Finkel B , Lerner AG , Kretzmer G , Sigal M . Dose-dependent olanzapine-associated leukopenia: three case reports. Int Clin Psychopharmacol 2001;16(2):117–19.
Carrillo JA , Gonzalez JA , Gervasini G , Lopez R , Fernandez MA , Nunez GM . Thrombocytopenia and fatality associated with olanzapine. Eur J Clin Pharmacol 2004;60(4):295–6.
Clark N , Weissberg E , Noel J . Quetiapine and leukopenia. Am J Psychiatry 2001;158(5):817–18.
Cowan C , Oakley C . Leukopenia and neutropenia induced by quetiapine. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(1):292–4.
Finkel B , Lerner AG , Oyffe I , Sigal M . Risperidone-associated agranulocytosis. Am J Psychiatry 1998;155(6):855–6.
Sluys M , Guzelcan Y , Casteelen G , de Haan L . Risperidone-induced leucopenia and neutropenia: a case report. Eur Psychiatry 2004;19(2):117.
Pfizer Canada Inc . Zeldox (Ziprasidone hydrochloride) Canadian Product Monograph. Quebec, Canada: Pfizer Canada Inc.; 2007.
Montgomery J . Ziprasidone-related agranulocytosis following olanzapine-induced neutropenia. Gen Hosp Psychiatry 2006;28(1):83–5.
American Society of Health-System Pharmacists . Antipsychotics. In McEvoy GK , ed., AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2009.
Thomson Reuters (Healthcare) Inc . Phenothiazine-induced agranulocytosis and leukopenia. In DRUGDEX® System (internet database) . Greenwood Village, CO: Thomson Reuters (Healthcare) Inc.; 2009 (cited July 9, 2009). Available from: http://www.thomsonhc.com.
Thomson Reuters (Healthcare) Inc . Thiothixene. In DRUGDEX® System (internet database) . Greenwood Village, CO: Thomson Reuters (Healthcare) Inc.; 2009 (cited July 9, 2009). Available from: http://www.thomsonhc.com.
Thomson Reuters (Healthcare) Inc . Haloperidol. In DRUGDEX® System (internet database) . Greenwood Village, CO: Thomson Reuters (Healthcare) Inc.; 2009 (cited July 9, 2009). Available from: http://www.thomsonhc.com.
Thomson Reuters (Healthcare) Inc . Molindone. In DRUGDEX® System (internet database) . Greenwood Village, CO: Thomson Reuters (Healthcare) Inc.; 2009 (cited July 10, 2009). Available from: http://www.thomsonhc.com.
Thomson Reuters (Healthcare) Inc . Loxapine. In DRUGDEX® System (internet database) . Greenwood Village, CO: Thomson Reuters (Healthcare) Inc.; 2009 (cited July 10, 2009). Available from: http://www.thomsonhc.com.
Kratz A , Ferraro M , Sluss PM , Lewandrowski KB . Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. N Engl J Med 2004;351(15):1548–63.
Novartis Pharmaceuticals Corporation . Clozaril (Clozapine) U.S. Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.

Reference Title: References

Reference Type: reference-list

Tune LE . Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 2001;62 Suppl. 21: 11–14.
Pappano AJ . Cholinoceptor-blocking drugs. In Katzung BG , Masters SB , Trevor AJ , eds., Basic and Clinical Pharmacology, 11th edn. New York/London: The McGraw-Hill Companies, Inc.; 2009.
Roe CM , Anderson MJ , Spivack B . Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc 2002;50(5):836–42.
Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999;60 Suppl. 10:5–14.
American Society of Health-System Pharmacists . Antimuscarinics/antispasmodics. In McEvoy GK , ed., AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2007.
Bezchlibnyk-Butler KZ , Jeffries JJ . Antipsychotics (neuroleptics). In Bezchlibnyk-Butler KZ , Jeffries JJ , eds., Clinical Handbook of Psychotropic Drugs, 16th edn. Toronto: Hogrefe & Huber Publishers; 2006; p. 77.
Gardner DM , Baldessarini RJ , Waraich P . Modern antipsychotic drugs: a critical overview. CMAJ 2005 172(13):1703–11.
Baldessarini RJ , Tarazi FI . Pharmacotherapy of psychosis and mania. In Brunton LL , Lazo JS , Parker K , eds., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn. New York: McGraw-Hill; 2006.
Chew ML , Mulsant BH , Pollock BG , et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006;88(1–3):63–72.
Bristol-Myers Squibb, Otsuka America Pharmaceutical . Abilify (Aripiprazole) U.S. Full Prescribing Information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd.; 2008.
de Leon J , Odom-White A , Josiassen RC , Diaz FJ , Cooper TB , Simpson GM . Serum antimuscarinic activity during clozapine treatment. J Clin Psychopharmacol 2003;23(4):336–41.
Erickson B , Morris DM , Reeve A . Clozapine-associated postoperative ileus: case report and review of the literature. Arch Gen Psychiatry 1995;52(6):508–9.
Rondla S , Crane S . A case of clozapine-induced paralytic ileus. Emerg Med J 2007;24(2):e12.
Hayes G , Gibler B. Clozapine-induced constipation. Am J Psychiatry 1995;152(2):298.
Chengappa KN , Pollock BG , Parepally H , et al. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J Clin Psychopharmacol 2000;20(3):311–16.
Lim CJ , Trevino C , Tampi RR . Can olanzapine cause delirium in the elderly? Ann Pharmacother 2006;40(1):135–8.
Bishara D , Taylor D . Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008;68(16):2269–92.
Janssen-Ortho Inc . Invega (Paliperidone) Canadian Product Monograph. Toronto, Canada: Janssen-Ortho Inc.; 2008.
Bagnall AM , Jones L , Ginnelly L , et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 2003;7(13):1–193.
Peuskens J , Link CG . A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96(4):265–73.
Arana GW . An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 2000;61 Suppl. 8:5–11; discussion 12–13.

Reference Title: References

Reference Type: reference-list

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee . Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32 Suppl. 1:S1–201.
American Diabetes Association . Standards of medical care in diabetes – 2009. Diabetes Care 2009; 32 Suppl. 1:S13–61.
Bushe C , Holt R . Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl 2004;47:S67–71.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity . Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27(2):596–601.
Melkersson K , Dahl ML . Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004;64(7):701–23.
Melkersson KI , Dahl ML , Hulting AL . Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology (Berl) 2004;175(1):1–6.
Cohen D , Correll CU . Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need. J Clin Psychiatry 2009;70(5):765–6.
Stahl SM , Mignon L , Meyer JM . Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009;119(3):171–9.
Travis MJ , Burns T , Dursun S , et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract 2005;59(4):485–95.
Yood MU , Delorenze G , Quesenberry CP, Jr , et al. The incidence of diabetes in atypical antipsychotic users differs according to agent – results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009;18(9):79–9.
Church CO , Stevens DL , Fugate SE . Diabetic ketoacidosis associated with aripiprazole. Diabet Med 2005;22(10):1440–3.
Dhamija R , Verma R . Diabetic ketoacidosis induced by aripiprazole in a 12-year-old boy. Diabetes Care 2008;31(6):e50.
Makhzoumi ZH , McLean LP , Lee JH , Ibe AI . Diabetic ketoacidosis associated with aripiprazole. Pharmacotherapy 2008;28(9):1198–202.
Reddymasu S , Bahta E , Levine S , Manas K , Slay LE . Elevated lipase and diabetic ketoacidosis associated with aripiprazole. JOP 2006;7(3):303–5.
Campanella LM , Lartey R , Shih R . Severe hyperglycemic hyperosmolar nonketotic coma in a nondiabetic patient receiving aripiprazole. Ann Emerg Med 2009;53(2):264–6.
Gianfrancesco FD , Grogg AL , Mahmoud RA , Wang RH , Nasrallah HA . Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002;63(10):920–30.
Lambert B , Chou CH , Chang KY , Iwamoto T , Tafesse E . Assessing the risk of antipsychotic-induced type II diabetes among schizophrenics: a matched case–control study. Eur J Neuropsychopharmacology 2002;12 Suppl. 3:S307–8.
Sernyak MJ , Leslie DL , Alarcon RD , Losonczy MF , Rosenheck R . Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159(4):561–6.
Lindenmayer JP , Czobor P , Volavka J , et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160(2):290–6.
Hedenmalm K , Hagg S , Stahl M , Mortimer O , Spigset O. Glucose intolerance with atypical antipsychotics. Drug Saf 2002;25(15):1107–16.
Smith M , Hopkins D , Peveler RC , Holt RI , Woodward M , Ismail K . First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2008;192(6):406–11.
McEvoy JP , Lieberman JA , Stroup TS , et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163(4):600–10.
Koro CE , Fedder DO , L'Italien GJ , et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case–control study. BMJ 2002;325(7358):243.
Gianfrancesco F , White R , Wang RH , Nasrallah HA . Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003;23(4):328–35.
Fuller MA , Shermock KM , Secic M , Grogg AL . Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003;23(8):1037–43.
Caro JJ , Ward A , Levinton C , Robinson K . The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002;63(12):1135–9.
Lieberman JA , Stroup TS , McEvoy JP , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209–23.
Janssen-Ortho Inc . Invega (Paliperidone) Canadian Product Monograph. Toronto, Canada: Janssen-Ortho Inc.; 2009.
Pfizer Canada Inc . Zeldox (Ziprasidone hydrochloride) Canadian Product Monograph. Quebec, Canada: Pfizer Canada Inc.; 2007.
Sanchez-Barranco P . New onset of diabetes mellitus with ziprasidone: a case report. J Clin Psychiatry 2005;66(2):268–9.
Yang SH , McNeely MJ . Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. Am J Psychiatry 2002;159(8):1435.
Haddad PM . Antipsychotics and diabetes: review of non-prospective data. Br J Psychiatry Suppl 2004;47:S80–6.
Liebzeit KA , Markowitz JS , Caley CF . New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001;11(1):25–32.

Reference Title: References

Reference Type: reference-list

Grundy SM , Pasternak R , Greenland P , Smith S, Jr , Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100(13):1481–92.
McPherson R , Frohlich J , Fodor G , Genest J , Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement – recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22(11):913–27.
Osby U , Correia N , Brandt L , Ekbom A , Sparen P . Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45(1–2):21–8.
Osby U , Brandt L , Correia N , Ekbom A , Sparen P . Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001;58(9):844–50.
Genest J , Frohlich J , Fodor G , McPherson R , Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003;169(9):921–4.
Grundy SM , Cleeman JI , Merz CN , et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110(2):227–39.
Eckel RH , Alberti KG , Grundy SM , Zimmet PZ . The metabolic syndrome. Lancet 2010;375(9710):181–3.
Wirshing DA , Pierre JM , Erhart SM , Boyd JA . Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatr Clin North Am 2003;26(1):165–90.
Meyer JM , Koro CE . The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004;70(1):1–17.
Lieberman JA , Stroup TS , McEvoy JP , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209–23.
Koro CE , Meyer JM . Atypical antipsychotic therapy and hyperlipidemia: a review. Essent Psychopharmacol 2005;6(3):148–57.
Travis MJ , Burns T , Dursun S , et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract 2005;59(4):485–95.
Olfson M , Marcus SC , Corey-Lisle P , Tuomari AV , Hines P , L'Italien GJ . Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006;163(10):1821–5.
Melkersson K , Dahl ML . Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004;64(7):701–23.
Melkersson KI , Dahl ML , Hulting AL . Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose–insulin homeostasis and lipid metabolism. Psychopharmacology (Berl) 2004;175(1):1–6.
Koro CE , Fedder DO , L'Italien GJ , et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59(11):1021–6.
Meyer JM . A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63(5):425–33.
Wirshing DA , Boyd JA , Meng LR , Ballon JS , Marder SR , Wirshing WC . The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63(10):856–65.
Janssen-Ortho Inc . Invega (Paliperidone) Canadian Product Monograph. Toronto, Canada: Janssen-Ortho Inc.; 2009.
Clark M , Dubowski K , Colmore J . The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clin Pharmacol Ther 1970;11(6):883–9.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285(19):2486–97.

Reference Title: References

Reference Type: reference-list

Marder SR , Essock SM , Miller AL , et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161(8):1334–49.
Osser DN . Neuroleptic-induced pseudoparkinsonism. In Young RR , Joseph AB , eds., Movement Disorders in Neurology and Neuropsychiatry, 3rd edn. Malden, MA: Blackwell Science, Inc.; 1999.
Miller LG , Jankovic J . Drug-induced dyskinesia: an overview. In Young RR , Joseph AB , eds., Movement Disorders in Neurology and Neuropsychiatry, 3rd edn. Malden, MA: Blackwell Science, Inc.; 1999.
Tarsy D . Akathisia. In Young RR , Joseph AB , eds., Movement Disorders in Neurology and Neuropsychiatry, 3rd edn. Malden, MA: Blackwell Science, Inc.; 1999.
Casey DE . Rabbit syndrome. In Young RR , Joseph AB , eds., Movement Disorders in Neurology and Neuropsychiatry, 3rd edn. Malden, MA: Blackwell Science, Inc.; 1999.
Catena Dell'osso M , Fagiolini A , Ducci F , Masalehdan A , Ciapparelli A , Frank E . Newer antipsychotics and the rabbit syndrome. Clin Pract Epidemiol Ment Health 2007;3:6.
Leucht S , Pitschel-Walz G , Abraham D , Kissling W . Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35(1):51–68.
Leucht S , Wahlbeck K , Hamann J , Kissling W . New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361(9369):1581–9.
Rosenheck R , Perlick D , Bingham S , et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290(20):2693–702.
Miller del D , Caroff SN , Davis SM , et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008;193(4):279–88.
Gardner DM , Baldessarini RJ , Waraich P . Modern antipsychotic drugs: a critical overview. CMAJ 2005;172(13):1703–11.
Bristol-Myers Squibb , Otsuka America Pharmaceutical . Abilify (Aripiprazole) U.S. Full Prescribing Information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd.; 2008.
Caykoylu A , Ekinci O , Kuloglu M , Deniz O . Aripiprazole-induced rabbit syndrome: a case report. J Psychopharmacol 2010;24(3):429–31.
Gonidakis F , Ploubidis D , Papadimitriou G . Aripiprazole-induced rabbit syndrome in a drug-naive schizophrenic patient. Schizophr Res 2008;103(1–3):341–2.
Essali A , Al-Haj Haasan N , Li C , Rathbone J . Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2009;(1):CD000059.
Tuunainen A , Wahlbeck K , Gilbody SM . Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst Rev 2000;(2):CD000966.
Meltzer HY , Alphs L , Green AI , et al. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry 2003;60(1):82–91.
Davydov L , Botts SR . Clozapine-induced hypersalivation. Ann Pharmacother 2000;34(5):662–5.
Duggan L , Fenton M , Rathbone J , Dardennes R , El-Dosoky A , Indran S . Olanzapine for schizophrenia. Cochrane Database Syst Rev 2005;(2):CD001359.
Tran PV , Hamilton SH , Kuntz AJ , et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17(5):407–18.
Conley RR , Mahmoud R . A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158(5):765–74.
Praharaj SK , Sarkar S , Jana AK , Sinha VK . Olanzapine-induced rabbit syndrome. South Med J 2008;101(10):1069–70.
Srisurapanont M , Maneeton B , Maneeton N . Quetiapine for schizophrenia. Cochrane Database Syst Rev 2004;(2):CD000967.
Mullen J , Jibson MD , Sweitzer D . A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001;23(11):1839–54.
Wu CC , Su KP . Quetiapine-induced rabbit syndrome in a patient with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(8):2002–3.
Janssen-Ortho Inc . Invega (Paliperidone) Canadian Product Monograph. Toronto, Canada: Janssen-Ortho Inc.; 2009.
Hunter RH , Joy CB , Kennedy E , Gilbody SM , Song F . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2003;(2):CD000440.
Gilbody SM , Bagnall AM , Duggan L , Tuunainen A . Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2000;(3):CD002306.
Pfizer Canada Inc . Zeldox (Ziprasidone hydrochloride) Canadian Product Monograph. Quebec, Canada: Pfizer Canada Inc.; 2007.
Kutcher S , Brooks SJ , Gardner DM , et al. Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders. Neuropsychiatr Dis Treat 2005;1(2):89–108.
Lieberman JA , Stroup TS , McEvoy JP , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209–23.
Lieberman JA , Phillips M , Gu H , et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003;28(5):995–1003.
Conley RR , Tamminga CA , Bartko JJ , et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155(7):914–20.
Lieberman JA , Tollefson G , Tohen M , et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160(8):1396–404.
Chouinard G , Margolese HC . Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res 2005;76(2–3):247–65.

Reference Title: References

Reference Type: reference-list

Farkas J , Farkas P , Hyde D . Liver and gastroenterology tests. In Lee M , American Society of Health-System Pharmacists , ed., Basic Skills in Interpreting Laboratory Data, 3rd edn. Bethesda, MD: American Society of Health-System Pharmacists; 2004.
Diehl AM . Hepatic complications of obesity. Gastroenterol Clin North Am 2005;34(1):45–61.
Arana GW . An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 2000;61 Suppl. 8:5–11; discussion 12–3.
Bénichou C . Adverse Drug Reactions : a Practical Guide to Diagnosis and Management. New York, NY: J. Wiley & Sons; 1994.
Oyewumi LK , De Wit R . Managing Side Effects of Psychotropic Drugs: a Clinical Handbook for Health Care Professionals. London, ON: Zxmaxx Communications; 1998.
Cuffel BJ , Heithoff KA , Lawson W . Correlates of patterns of substance abuse among patients with schizophrenia. Hosp Community Psychiatry 1993;44(3):247–51.
Kratz A , Ferraro M , Sluss PM , Lewandrowski KB . Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. N Engl J Med 2004;351(15):1548–63.
Bristol-Myers Squibb, Otsuka America Pharmaceutical . Abilify (Aripiprazole) U.S. Full Prescribing Information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd.; 2008.
Macfarlane B , Davies S , Mannan K , Sarsam R , Pariente D , Dooley J . Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology 1997;112(5):1707–9.
Hummer M , Kurz M , Kurzthaler I , Oberbauer H , Miller C , Fleischhacker WW . Hepatotoxicity of clozapine. J Clin Psychopharmacol 1997;17(4):314–17.
Chang A , Krygier DS , Chatur N , Yoshida EM . Clozapine-induced fatal fulminant hepatic failure: a case report. Can J Gastroenterol 2009;23(5):376–8.
Canadian Pharmacists Association . Zyprexa (olanzapine) product monograph. In Canadian Pharmacists Association , ed., Compendium of Pharmaceuticals and Specialties. Toronto; 2006.
Tran PV , Hamilton SH , Kuntz AJ , et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17(5):407–18.
Raz A , Bergman R , Eilam O , Yungerman T , Hayek T . A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci 2001;321(2):156–8.
Jadallah KA , Limauro DL , Colatrella AM . Acute hepatocellular-cholestatic liver injury after olanzapine therapy. Ann Intern Med 2003;138(4):357–8.
Ozcanli T , Erdogan A , Ozdemir S , et al. Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(6):1163–6.
Canadian Pharmacists Association . Seroquel (quetiapine) product monograph. In Canadian Pharmacists Association , ed., Compendium of Pharmaceuticals and Specialties. Toronto; 2006.
El Hajj I , Sharara AI , Rockey DC . Subfulminant liver failure associated with quetiapine. Eur J Gastroenterol Hepatol 2004;16(12):1415–18.
Wright TM , Vandenberg AM . Risperidone- and quetiapine-induced cholestasis. Ann Pharmacother 2007;41(9):1518–23.
Shpaner A , Li W , Ankoma-Sey V , Botero RC . Drug-induced liver injury: hepatotoxicity of quetiapine revisited. Eur J Gastroenterol Hepatol 2008;20(11):1106–9.
Landau J , Martin A . Is liver function monitoring warranted during risperidone treatment? J Am Acad Child Adolesc Psychiatry 1998;37(10):1007–8.
Kumra S , Herion D , Jacobsen LK , Briguglia C , Grothe D . Case study: risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 1997;36(5):701–5.
Benazzi F . Risperidone-induced hepatotoxicity. Pharmacopsychiatry 1998;31(6):241.
Krebs S , Dormann H , Muth-Selbach U , Hahn EG , Brune K , Schneider HT . Risperidone-induced cholestatic hepatitis. Eur J Gastroenterol Hepatol 2001;13(1):67–9.
Llinares Tello F , Hernandez Prats C , Bosacoma Ros N , et al. Acute cholestatic hepatitis probably associated with risperidone. Int J Psychiatry Med 2005;35(2):199–205.
Cordeiro Q, Jr , Elkis H . Pancreatitis and cholestatic hepatitis induced by risperidone. J Clin Psychopharmacol 2001;21(5):529–30.
Fuller MA , Simon MR , Freedman L . Risperidone-associated hepatotoxicity. J Clin Psychopharmacol 1996;16(1):84–5.
Phillips EJ , Liu BA , Knowles SR . Rapid onset of risperidone-induced hepatotoxicity. Ann Pharmacother 1998;32(7–8):843.
Pfizer Canada Inc . Zeldox (Ziprasidone hydrochloride) Canadian Product Monograph. Quebec, Canada: Pfizer Canada Inc.; 2007.
Selim K , Kaplowitz N . Hepatotoxicity of psychotropic drugs. Hepatology 1999 May;29(5):1347–51.
Jones JK , Van de Carr SW , Zimmerman H , Leroy A . Hepatotoxicity associated with phenothiazines. Psychopharmacol Bull 1983;19(1):24–7.
Dincsoy HP , Saelinger DA . Haloperidol-induced chronic cholestatic liver disease. Gastroenterology 1982;83(3):694–700.
Dumortier G , Cabaret W , Stamatiadis L , et al. Hepatic tolerance of atypical antipsychotic drugs. Encephale 2002;28(6):542–51.

Reference Title: References

Reference Type: reference-list

Pelonero AL , Levenson JL , Pandurangi AK . Neuroleptic malignant syndrome. In Young RR , Joseph AB , eds., Movement Disorders in Neurology and Neuropsychiatry, 3rd edn. Malden, MA: Blackwell Science, Inc.; 1999.
Strawn JR , Keck PE, Jr , Caroff SN . Neuroleptic malignant syndrome. Am J Psychiatry 2007;164(6):870–6.
Stubner S , Rustenbeck E , Grohmann R , et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 2004;37 Suppl. 1:S54–64.
Rosebush PI , Mazurek MF . Serum iron and neuroleptic malignant syndrome. Lancet 1991;338(8760):149–51.
Hasan S , Buckley P . Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998;155(8):1113–6.
Picard LS , Lindsay S , Strawn JR , Kaneria RM , Patel NC , Keck PE , Jr. Atypical neuroleptic malignant syndrome: Diagnostic controversies and considerations. Pharmacotherapy 2008;28(4):530–5.
Caroff SN . Neuroleptic malignant syndrome: still a risk, but which patients may be in danger? Curr Psychiatry 2003;2:36–42.
Tarsy D , Baldessarini RJ . Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006;21(5):589–98.
Karagianis J , Phillips L , Hogan K , LeDrew K . Re: neuroleptic malignant syndrome associated with quetiapine. Can J Psychiatry 2001;46(4):370–1.
Sachdev P , Kruk J , Kneebone M , Kissane D . Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol 1995;15(5):365–71.
Ananth J , Parameswaran S , Gunatilake S , Burgoyne K , Sidhom T . Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65(4):464–70.

Reference Title: References

Reference Type: reference-list

Melkersson KI , Dahl ML , Hulting AL . Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology (Berl) 2004;175(1):1–6.
Ryan MC , Flanagan S , Kinsella U , Keeling F , Thakore JH . The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004;74(16):1999–2008.
Allison DB , Casey DE . Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62 Suppl. 7:22–31.
Koponen H , Saari K , Savolainen M , Isohanni M . Weight gain and glucose and lipid metabolism disturbances during antipsychotic medication: a review. Eur Arch Psychiatry Clin Neurosci 2002;252(6):294–8.
Allison DB , Mentore JL , Heo M , et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156(11):1686–96.
Sussman N . Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001;62 Suppl. 23:5–12.
Nasrallah H . A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003;28 Suppl. 1:83–96.
Lieberman JA , Stroup TS , McEvoy JP , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209–23.
Newcomer JW . Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68 Suppl. 4:8–13.
Muller DJ , Kennedy JL . Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006;7(6):863–87.
Chagnon YC . Susceptibility genes for the side effect of antipsychotics on body weight and obesity. Curr Drug Targets 2006;7(12):1681–95.
Reynolds GP , Hill MJ , Kirk SL . The 5-HT2C receptor and antipsychotic-induced weight gain – mechanisms and genetics. J Psychopharmacol 2006;20(4 Suppl.):15–18.
Rege S . Antipsychotic induced weight gain in schizophrenia: mechanisms and management. Aust N Z J Psychiatry 2008;42(5):369–81.
National Institutes of Health . Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults – the evidence report. Obes Res 1998;6 Suppl. 2:51S–209S.
Lau DC , Douketis JD , Morrison KM , et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ 2007;176(8 Suppl.):online 1–117.
Kurzthaler I , Fleischhacker WW . The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 2001;62 Suppl. 7:32–7.
Douketis JD , Feightner JW , Attia J , Feldman WF . Periodic health examination, 1999 update: 1. Detection, prevention and treatment of obesity. Canadian Task Force on Preventive Health Care. CMAJ 1999;160(4):513–25.
Janssen I , Katzmarzyk PT , Ross R . Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. Arch Intern Med 2002;162(18):2074–9.
Blin O , Micallef J . Antipsychotic-associated weight gain and clinical outcome parameters. J Clin Psychiatry 2001;62 Suppl. 7:11–21.
Wirshing DA , Pierre JM , Erhart SM , Boyd JA . Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatr Clin North Am 2003;26(1):165–90.
Travis MJ , Burns T , Dursun S , et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract 2005;59(4):485–95.
Lambert TJ . Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder. Evid Based Ment Health 2009;12(2):50.
Newcomer JW , Campos JA , Marcus RN , et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 2008;69(7):1046–56.
Bristol-Myers Squibb , Otsuka America Pharmaceutical. Abilify (Aripiprazole) U.S. Full Prescribing Information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd.; 2008.
Henderson DC , Cagliero E , Gray C , et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000;157(6):975–81.
Bobes J , Rejas J , Garcia-Garcia M , et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 2003;62(1–2):77–88.
McEvoy JP , Lieberman JA , Perkins DO , et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164(7):1050–60.
Janssen-Ortho Inc . Invega (Paliperidone) Canadian Product Monograph. Toronto, Canada: Janssen-Ortho Inc.; 2008.

Reference Title: References

Reference Type: reference-list

Taylor F . Drugs affecting the eye. Aust Fam Physician 1985;14(8):744–5.
Sutton AL . Eye Care Sourcebook: Basic Consumer Health Information About Eye Care and Eye Disorders, 2nd edn. Detroit, MI: Omnigraphics; 2003.
Yanoff M , Duker JS . Ophthalmology, 2nd edn. London; St. Louis, MO: Mosby; 2004.
McCarty CA , Wood CA , Fu CL , et al. Schizophrenia, psychotropic medication, and cataract. Ophthalmology 1999;106(4):683–7.
Abraham AG , Condon NG , West Gower E . The new epidemiology of cataract. Ophthalmol Clin North Am 2006;19(4):415–25.
Hodge WG , Whitcher JP , Satariano W . Risk factors for age-related cataracts. Epidemiol Rev 1995;17(2):336–46.
Harper RA , Shock JP . Lens. In Riordan-Eva P , Whitcher JP , eds., Vaughan & Asbury's General Ophthalmology, 17th edn. USA: McGraw-Hill Companies, Inc.; 2008.
Marder SR , Essock SM , Miller AL , et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161(8):1334–49.
Novais e Souza VB , de Moura Filho FJ , de Matos e Souza FG , et al. Cataract occurrence in patients treated with antipsychotic drugs. Rev Bras Psiquiatr 2008;30(3):222–6.
Ruigomez A , Garcia Rodriguez LA , Dev VJ , Arellano F , Raniwala J . Are schizophrenia or antipsychotic drugs a risk factor for cataracts? Epidemiology 2000;11(6):620–3.
Borovik AM , Bosch MM , Watson SL . Ocular pigmentation associated with clozapine. Med J Aust 2009;190(4):210–11.
AstraZeneca Canada Inc . Seroquel XR (Quetiapine fumarate) Canadian Product Monograph. Mississauga, ON: AstraZeneca Canada Inc.; 2009.
Stip E , Boisjoly H . Quetiapine: are we overreacting in our concern about cataracts (the beagle effect)? Can J Psychiatry 1999;44(5):503.
Nasrallah HA , Tandon R . Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. J Clin Psychiatry 2002;63 Suppl. 13:12–20.
Shahzad S , Suleman MI , Shahab H , et al. Cataract occurrence with antipsychotic drugs. Psychosomatics 2002;43(5):354–9.
Bristol-Myers Squibb , Otsuka America Pharmaceutical . Abilify (Aripiprazole) U.S. Full Prescribing Information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd.; 2008.
Janssen-Ortho Inc . Invega (Paliperidone) Canadian Product Monograph. Toronto, Canada: Janssen-Ortho Inc.; 2009.
Leung AT , Cheng AC , Chan WM , Lam DS . Chlorpromazine-induced refractile corneal deposits and cataract. Arch Ophthalmol 1999;117(12):1662–3.
Webber SK , Domniz Y , Sutton GL , Rogers CM , Lawless MA . Corneal deposition after high-dose chlorpromazine hydrochloride therapy. Cornea 2001;20(2):217–19.
Razeghinejad MR , Nowroozzadeh MH , Zamani M , Amini N . In vivo observations of chlorpromazine ocular deposits in a patient on long-term chlorpromazine therapy. Clin Experiment Ophthalmol 2008;36(6):560–3.
Shah GK , Auerbach DB , Augsburger JJ , Savino PJ . Acute thioridazine retinopathy. Arch Ophthalmol 1998;116(6):826–7.
Orlin SE . Cataracts. In American College of Physicians , ed., ACP PIER & AHFS DI Essentials. Philadelphia, PA: American College of Physicians; 2009.

Reference Title: References

Reference Type: reference-list

Mancini T , Casanueva FF , Giustina A . Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 2008;37(1):67–99, viii.
Ben-Jonathan N , Hugo ER , Brandebourg TD , LaPensee CR . Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 2006;17(3):110–16.
Baldessarini RJ , Tarazi FI . Pharmacotherapy of psychosis and mania. In Brunton LL , Lazo JS , Parker KL , eds., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn. USA: McGraw-Hill; 2006.
Martin JH . Neuroanatomy Text and Atlas, 3rd edn. USA: McGraw-Hill Companies, Inc; 2003.
Kuruvilla A , Peedicayil J , Srikrishna G , Kuruvilla K , Kanagasabapathy AS . A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 1992;19(9):603–6.
Hamner MB , Arana GW . Hyperprolactinaemia in antipsychotic-treated patients: guidelines for avoidance and management. CNS Drugs 1998;10(3):209–222.
Halbreich U , Kinon BJ , Gilmore JA , Kahn LS . Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003;28 Suppl. 1:53–67.
Kinon BJ , Gilmore JA , Liu H , Halbreich UM . Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 2003;28 Suppl. 2:69–82.
Wieck A , Haddad PM . Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003;182:199–204.
Byerly M , Suppes T , Tran QV , Baker RA . Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 2007;27(6):639–61.
Bostwick JR , Guthrie SK , Ellingrod VL . Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 2009;29(1):64–73.
Wieck A , Haddad PM . Hyperprolactinemia. In Haddad PM , Dursun S , Deakin B , eds., Adverse Syndromes and Psychiatric Drugs. Oxford, UK: Oxford University Press; 2004.
Lehman AF , Lieberman JA , Dixon LB , et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(2 Suppl.):1–56.
Potkin SG , Saha AR , Kujawa MJ , et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60(7):681–90.
Byerly MJ , Marcus RN , Tran QV , Eudicone JM , Whitehead R , Baker RA . Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res 2009;107(2–3):218–22.
Volavka J , Czobor P , Cooper TB , et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004;65(1):57–61.
David SR , Taylor CC , Kinon BJ , Breier A . The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000;22(9):1085–96.
Crawford AM , Beasley CM , Jr, Tollefson GD . The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997;26(1):41–54.
Tran PV , Hamilton SH , Kuntz AJ , et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17(5):407–18.
Janssen-Ortho Inc . Invega (Paliperidone) Canadian Product Monograph. Toronto, Canada: Janssen-Ortho Inc.; 2009.
Kane J , Canas F , Kramer M , et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90(1–3):147–61.
Knegtering R , Baselmans P , Castelein S , Bosker F , Bruggeman R , van den Bosch RJ . Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005;162(5):1010–12.
Atmaca M , Kuloglu M , Tezcan E , Canatan H , Gecici O . Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. Arch Med Res 2002;33(6):562–5.
Copolov DL , Link CG , Kowalcyk B . A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘seroquel’) and haloperidol in schizophrenia. Psychol Med 2000;30(1):95–105.
Schooler N , Rabinowitz J , Davidson M , et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005;162(5):947–53.
Lieberman JA , Stroup TS , McEvoy JP , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209–23.
Bezchlibnyk-Butler KZ , Jeffries JJ . Clinical Handbook of Psychotropic Drugs, 4th rev. edn. Toronto: Hogrefe & Huber Publishers; 1993.
Kinon BJ , Gilmore JA , Liu H , Halbreich UM . Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28 Suppl. 2: 55–68.
Pfizer Canada Inc . Zeldox (Ziprasidone hydrochloride) Canadian Product Monograph. Quebec, Canada: Pfizer Canada Inc.; 2007.
Kane JM , Khanna S , Rajadhyaksha S , Giller E . Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2006;21(1):21–8.
Weiden PJ , Daniel DG , Simpson G , Romano SJ . Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003;23(6):595–600.
Weiden PJ , Simpson GM , Potkin SG , O'Sullivan RL . Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003;64(5):580–8.
Haddad PM , Wieck A . Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64(20):2291–314.
Kleinberg DL , Davis JM , de Coster R , Van Baelen B , Brecher M . Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19(1):57–61.
Citrome L . Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol 2008;22(2 Suppl.):90–7.
Kratz A , Ferraro M , Sluss PM , Lewandrowski KB . Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. N Engl J Med 2004;351(15):1548–63.

Reference Title: References

Reference Type: reference-list

Al-Khatib SM , LaPointe NM , Kramer JM , Califf RM . What clinicians should know about the QT interval. JAMA 2003;289(16):2120–7.
Goldfrank LR , Flomenbaum N . Goldfrank's Toxicologic Emergencies, 8th edn. New York: McGraw-Hill, Medical Publishing Division; 2006.
Haddad PM , Anderson IM . Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62(11):1649–71.
Committee for Proprietary Medicinal Products . Points to Consider: the Assessment of the Potential for QT Interval Prolongation by Non-cardiovascular Medicinal Products. London, UK: The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit; 1997.
Straus SM , Kors JA , De Bruin ML , et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006;47(2):362–7.
Zareba W , Lin DA . Antipsychotic drugs and QT interval prolongation. Psychiatr Q 2003;74(3):291–306.
Ray WA , Chung CP , Murray KT , Hall K , Stein CM . Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360(3):225–35.
Schneeweiss S , Avorn J . Antipsychotic agents and sudden cardiac death – how should we manage the risk? N Engl J Med 2009;360(3):294–6.
US Food and Drug Administration . Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. US Food and Drug Administration; 2009.
Wang PS , Schneeweiss S , Avorn J , et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353(22):2335–41.
Calderone V , Testai L , Martinotti E , Del Tacca M , Breschi MC . Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics. J Pharm Pharmacol 2005;57(2):151–61.
Kutcher S , Brooks SJ , Gardner DM , et al. Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders. Neuropsychiatr Dis Treat 2005;1(2):89–108.
Ray WA , Meredith S , Thapa PB , Meador KG , Hall K , Murray KT . Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58(12):1161–7.
Straus SM , Bleumink GS , Dieleman JP , et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 2004;164(12):1293–7.
Liu BA , Juurlink DN . Drugs and the QT interval – caveat doctor. N Engl J Med 2004;351(11):1053–6.
Glassman AH , Bigger JT , Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158(11):1774–82.
Travis MJ , Burns T , Dursun S , et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract 2005;59(4):485–95.
Kang UG , Kwon JS , Ahn YM , et al. Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry 2000;61(6):441–6.
Warner B , Hoffmann P . Investigation of the potential of clozapine to cause torsade de pointes. Adverse Drug React Toxicol Rev 2002;21(4):189–203.
Hoehns JD , Fouts MM , Kelly MW , Tu KB . Sudden cardiac death with clozapine and sertraline combination. Ann Pharmacother 2001;35(7–8):862–6.
Killian JG , Kerr K , Lawrence C , Celermajer DS . Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354(9193):1841–5.
Novartis Pharmaceuticals Corporation . Important Drug Warning: Clozaril (Clozapine). East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2002.
Novartis Pharmaceuticals Canada Inc . Important Drug Safety Information: Association of Clozaril (Clozapine) with Cardiovascular Toxicity. Dorval, QC: Novartis Pharmaceuticals Canada Inc.; 2002.
La Grenade L , Graham D , Trontell A . Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 2001;345(3):224–5.
Czekalla J , Beasley CM , Jr, Dellva MA , Berg PH , Grundy S . Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psychiatry 2001;62(3):191–8.
Lieberman JA , Stroup TS , McEvoy JP , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209–23.
Harrigan EP , Miceli JJ , Anziano R , et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24(1):62–9.
Miceli J , Shiovitz T , Swift R , Anziano R , Tensfeldt T . High-dose ziprasidone is associated with marginal additional QTc increase (abstract of poster). In American Psychiatric Association 156th Annual Meeting; May 17–22, 2003; San Francisco, CA.
Glassman AH . Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 2005;66 Suppl. 6: 5–10.
Reilly JG , Ayis SA , Ferrier IN , Jones SJ , Thomas SH . QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000;355(9209):1048–52.
Reilly JG , Ayis SA , Ferrier IN , Jones SJ , Thomas SH . Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry 2002;180:515–22.

Reference Title: References

Reference Type: reference-list

Benson KL. Sleep in schizophrenia: impairments, correlates, and treatment. Psychiatr Clin North Am 2006;29(4):1033–45; abstract ix–x.
Krystal AD , Goforth HW , Roth T . Effects of antipsychotic medications on sleep in schizophrenia. Int Clin Psychopharmacol 200; 23(3):150–60.
Silber MH , Ancoli-Israel S , Bonnet MH , et al. The visual scoring of sleep in adults. J Clin Sleep Med 2007;3(2):121–31.
Monti JM , Monti D . Sleep in schizophrenia patients and the effects of antipsychotic drugs. Sleep Med Rev 2004;8(2):133–48.
Tandon R , Shipley JE , Taylor S , et al. Electroencephalographic sleep abnormalities in schizophrenia. Relationship to positive/negative symptoms and prior neuroleptic treatment. Arch Gen Psychiatry 1992;49(3):185–94.
Goder R , Fritzer G , Gottwald B , et al. Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia. Pharmacopsychiatry 2008;41(3):92–9.
Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004;6 Suppl. 2:3–7.
Lu B , Budhiraja R , Parthasarathy S. Sedating medications and undiagnosed obstructive sleep apnea: physician determinants and patient consequences. J Clin Sleep Med 2005;1(4):367–71.
Seale C , Chaplin R , Lelliott P , Quirk A . Antipsychotic medication, sedation and mental clouding: an observational study of psychiatric consultations. Soc Sci Med 2007;65(4):698–711.
Lieberman JA , Stroup TS , McEvoy JP , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209–23.
Stahl SM. Antipsychotic agents. In Stahl SM , ed., Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 3rd edn. New York, NY: Cambridge University Press; 2008.
Baldessarini RJ , Tarazi FI . Pharmacotherapy of psychosis and mania. In Brunton LL , Lazo JS , Parker K , eds., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn. New York: McGraw-Hill; 2006.
Richelson E , Souder T . Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68(1):29–39.
Richelson E . Pharmacology of neuroleptics in use in the United States. J Clin Psychiatry 1985;46(8):8–14.
Luthringer R , Staner L , Noel N , et al. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 2007;22(5):299–308.
Nussbaum A , Stroup TS . Paliperidone for schizophrenia. Cochrane Database Syst Rev 2008;(2):CD006369.
McQuade RD , Stock E , Marcus R , et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65 Suppl. 18:47–56.
Kane JM , Osuntokun O , Kryzhanovskaya LA , et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry 2009;70(4):572–81.
Zimbroff D , Warrington L , Loebel A , Yang R , Siu C . Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int Clin Psychopharmacol 2007;22(6):363–70.
Kasper S , Lerman MN , McQuade RD , et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6(4):325–37.
Tuunainen A , Wahlbeck K , Gilbody SM . Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst Rev 2000;(2):CD000966.
McEvoy JP , Lieberman JA , Stroup TS , et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163(4):600–10.
Desarkar P , Goyal N , Khess CR. Clozapine-induced cataplexy. J Neuropsychiatry Clin Neurosci 2007;19(1):87–8.
Blum A . Triad of hyperthermia, increased REM sleep, and cataplexy during clozapine treatment? J Clin Psychiatry 1990;51(6):259–60.
Chiles JA , Cohn S , McNaughton A. Dropping objects: possible mild cataplexy associated with clozapine. J Nerv Ment Dis 1990;178(10):663–4.
Duggal HS , Mendhekar DN. Clozapine-associated restless legs syndrome. J Clin Psychopharmacol 2007;27(1):89–90.
Khalid I , Rana L , Khalid TJ , Roehrs T . Refractory restless legs syndrome likely caused by olanzapine. J Clin Sleep Med 2009;5(1):68–9.
Kang SG , Lee HJ , Kim L. Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine. J Psychopharmacol 2009;23(5):597–601.
Chiu YH , Chen CH , Shen WW. Somnambulism secondary to olanzapine treatment in one patient with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(2):581–2.
Paquet V , Strul J , Servais L , Pelc I , Fossion P . Sleep-related eating disorder induced by olanzapine. J Clin Psychiatry 2002;63(7):597.
Kolivakis TT , Margolese HC , Beauclair L , Chouinard G. Olanzapine-induced somnambulism. Am J Psychiatry 2001;158(7):1158.
Kraus T , Schuld A , Pollmacher T . Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine. J Clin Psychopharmacol 1999;19(5):478–9.
Canuso CM , Dirks B , Carothers J , et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2009;166(6):691–701.
Cohrs S , Rodenbeck A , Guan Z , et al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl) 2004;174(3):421–9.
Calabrese JR , Keck PE , Jr, Macfadden W , et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162(7):1351–60.
Srisurapanont M , Maneeton B , Maneeton N . Quetiapine for schizophrenia. Cochrane Database Syst Rev 2004;(2):CD000967.
Urbano MR , Ware JC . Restless legs syndrome caused by quetiapine successfully treated with ropinirole in 2 patients with bipolar disorder. J Clin Psychopharmacol 2008;28(6):704–5.
Pinninti NR , Mago R , Townsend J , Doghramji K. Periodic restless legs syndrome associated with quetiapine use: a case report. J Clin Psychopharmacol 2005;25(6):617–18.
Hafeez ZH , Kalinowski CM . Somnambulism induced by quetiapine: two case reports and a review of the literature. CNS Spectr 2007;12(12):910–12.
Zhong KX , Sweitzer DE , Hamer RM , Lieberman JA . Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry 2006;67(7):1093–103.
Wetter TC , Brunner J , Bronisch T . Restless legs syndrome probably induced by risperidone treatment. Pharmacopsychiatry 2002;35(3):109–11.
Lu ML , Shen WW . Sleep-related eating disorder induced by risperidone. J Clin Psychiatry 2004;65(2):273–4.
Prueter C , Luecke FG , Hoff P . Pavor nocturnus as a side effect of a single daily risperidone dose. Gen Hosp Psychiatry 2005;27(4):300–1.
Komossa K , Rummel-Kluge C , Hunger H , et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;(4):CD006627.
Leucht C , Kitzmantel M , Chua L , Kane J , Leucht S . Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database Syst Rev 2008;(1):CD004278.
Essali A , Al-Haj Haasan N , Li C , Rathbone J . Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2009;(1):CD000059.
Adams CE , Awad G , Rathbone J , Thornley B . Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev 2007;(2):CD000284.
Hunter RH , Joy CB , Kennedy E , Gilbody SM , Song F . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2003;(2):CD000440.
Joy CB , Adams CE , Lawrie SM . Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev 2006;(4):CD003082.
Chakrabarti A , Bagnall A , Chue P , et al. Loxapine for schizophrenia. Cochrane Database Syst Rev 2007;(4):CD001943.
Sikich L , Frazier JA , McClellan J , et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008;165(11):1420–31.
Bagnall A , Fenton M , Kleijnen J , Lewis R . Molindone for schizophrenia and severe mental illness. Cochrane Database Syst Rev 2007;(1):CD002083.

Reference Title: References

Reference Type: reference-list

Gaitatzis A , Carroll K , Majeed A , W Sander J. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 2004;45(12):1613–22.
Alldredge BK . Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 1999;53(5 Suppl. 2):S68–75.
Remick RA , Fine SH . Antipsychotic drugs and seizures. J Clin Psychiatry 1979;40(2):78–80.
Lee KC , Finley PR , Alldredge BK . Risk of seizures associated with psychotropic medications: emphasis on new drugs and new findings. Expert Opin Drug Saf 2003;2(3):233–47.
Devinsky O , Pacia SV . Seizures during clozapine therapy. J Clin Psychiatry 1994;55 Suppl. B:153–6.
Yokota K , Tatebayashi H , Matsuo T , et al. The effects of neuroleptics on the GABA-induced Cl current in rat dorsal root ganglion neurons: differences between some neuroleptics. Br J Pharmacol 2002;135(6):1547–55.
Hedges D , Jeppson K , Whitehead P . Antipsychotic medication and seizures: a review. Drugs Today (Barc) 2003;39(7):551–7.
Koch-Stoecker S . Antipsychotic drugs and epilepsy: indications and treatment guidelines. Epilepsia 2002;43 Suppl. 2: 19–24.
Marks RC , Luchins DJ . Antipsychotic medications and seizures. Psychiatr Med 1991;9(1):37–52.
Herrmann N , Mamdani M , Lanctot KL . Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004;161(6):1113–15.
Pisani F , Oteri G , Costa C , Di Raimondo G , Di Perri R . Effects of psychotropic drugs on seizure threshold. Drug Saf 2002;25(2):91–110.
Logothetis J . Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology 1967;17(9):869–77.
Bristol-Myers Squibb , Otsuka America Pharmaceutical . Abilify (Aripiprazole) U.S. Full Prescribing Information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd.; 2008.
Malik AR , Ravasia S . Aripiprazole-induced seizure. Can J Psychiatry 2005;50(3):186.
Tsai JF . Aripiprazole-associated seizure. J Clin Psychiatry 2006;67(6):995–6.
Devinsky O , Honigfeld G , Patin J . Clozapine-related seizures. Neurology 1991;41(3):369–71.
Haddad PM , Sharma SG . Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007;21(11):911–36.
Lilly . Zyprexa (Olanzapine) Product Monograph. Toronto, Canada: Lilly; 2008.
Alper K , Schwartz KA , Kolts RL , Khan A . Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007;62(4):345–54.
Janssen-Ortho Inc . Invega (Paliperidone) Canadian Product Monograph. Toronto, Canada: Janssen-Ortho Inc.; 2009.
Janssen . Risperdal (Risperidone) U.S. Full Prescribing Information. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2006.
Pfizer Canada Inc . Zeldox (Ziprasidone hydrochloride) Canadian Product Monograph. Quebec, Canada: Pfizer Canada Inc.; 2007.

Reference Title: References

Reference Type: reference-list

American Psychiatric Association . Diagnostic and Statistical Manual – text revision, 4th edn. First MB , ed. Washington, DC: American Psychiatric Association; 2000.
Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol 2008;23(3):201–9.
Baldwin DS , Mayers AG , Lambert A . Sexual dysfunction. In Haddad PM , Dursun S , Deakin B , eds., Adverse Syndromes and Psychiatric Drugs. Oxford, UK: Oxford University Press; 2004.
Aizenberg D , Modai I , Landa A , Gil-Ad I , Weizman A . Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. J Clin Psychiatry 2001;62(7):541–4.
Laumann EO , Paik A , Rosen RC . Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281(6):537–44.
Laumann EO . Erratum: Sexual dysfunction in the United States: revalence and predictors (JAMA [February 10, 1999] 281(6):537–544]). JAMA 1999;281(13):1174.
Bitter I , Basson BR , Dossenbach MR . Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients. Int Clin Psychopharmacol 2005;20(1):19–21.
Macdonald S , Halliday J , MacEwan T , et al. Nithsdale Schizophrenia Surveys 24: sexual dysfunction. Case–control study. Br J Psychiatry 2003;182:50–6.
Patel AG , Mukherji K , Lee A . Priapism associated with psychotropic drugs. Br J Hosp Med 1996;55(6):315–19.
Sood S , James W , Bailon MJ . Priapism associated with atypical antipsychotic medications: a review. Int Clin Psychopharmacol 2008;23(1):9–17.
Segraves RT . Effects of psychotropic drugs on human erection and ejaculation. Arch Gen Psychiatry 1989;46(3):275–84.
Konarzewska B , Wolczynski S , Szulc A , Galinska B , Poplawska R , Waszkiewicz N . Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology 2009;34(1):129–39.
Dossenbach M , Hodge A , Anders M , et al. Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation. Int J Neuropsychopharmacol 2005;8(2):195–201.
Dossenbach M , Dyachkova Y , Pirildar S , et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry 2006;21(4):251–8.
Hanssens L , L'Italien G , Loze JY , Marcus RN , Pans M , Kerselaers W . The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 2008;8:95.
Mir A , Shivakumar K , Williamson RJ , McAllister V , O'Keane V , Aitchison KJ . Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol 2008;22(3):244–53.
Schlachetzki JC , Langosch JM . Aripiprazole induced hypersexuality in a 24-year-old female patient with schizoaffective disorder? J Clin Psychopharmacol 2008;28(5):567–8.
Mago R , Anolik R , Johnson RA , Kunkel EJ . Recurrent priapism associated with use of aripiprazole. J Clin Psychiatry 2006;67(9):1471–2.
Aguilar-Shea AL , Palomero-Juan I , Sierra Santos L , Gallardo-Mayo C . Aripiprazole and priapism. Aten Primaria 2009;41(4):230–1.
Strous RD , Kupchik M , Roitman S , et al. Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. Hum Psychopharmacol 2006;21(4):235–43.
Hummer M , Kemmler G , Kurz M , Kurzthaler I , Oberbauer H , Fleischhacker WW . Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. Am J Psychiatry 1999;156(4):631–3.
Kinon BJ , Ahl J , Liu-Seifert H , Maguire GA . Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 2006;31(5):577–88.
Bucur M , Mahmood T . Olanzapine-induced clitoral priapism. J Clin Psychopharmacol 2004;24(5):572–3.
Janssen-Ortho Inc . Invega (Paliperidone) Canadian Product Monograph. Toronto, Canada: Janssen-Ortho Inc.; 2009.
Byerly MJ , Nakonezny PA , Bettcher BM , Carmody T , Fisher R , Rush AJ . Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr Res 2006;86(1–3):244–50.
Montejo AL , Rico-Villademoros F , Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction . Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: a 3-month prospective, observational study. J Clin Psychopharmacol 2008;28(5):568–70.
Boora K , Chiappone K , Dubovsky S , Xu J . Ziprasidone-induced spontaneous orgasm. J Psychopharmacol 2009; doi:10.1177/0269881108100321.
Smith SM , O'Keane V , Murray R . Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 2002;181:49–55.
Kelly DL , Conley RR . Evaluating sexual function in patients with treatment-resistant schizophrenia. Schizophr Res 2003;63(1–2):195–6.
Keller A , McGarvey EL , Clayton AH . Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). J Sex Marital Ther 2006;32(1):43–52.
McGahuey CA , Gelenberg AJ , Laukes CA , et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26(1):25–40.

Reference Title: References

Reference Type: reference-list

Hockstein NG , Samadi DS , Gendron K , Handler SD . Sialorrhea: a management challenge. Am Fam Physician 2004;69(11):2628–34.
Praharaj SK , Arora M , Gandotra S . Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology (Berl) 2006;185(3):265–73.
Sockalingam S , Shammi C , Remington G . Clozapine-induced hypersalivation: a review of treatment strategies. Can J Psychiatry 2007;52(6):377–84.
Rabinowitz T , Frankenburg FR , Centorrino F , Kando J . The effect of clozapine on saliva flow rate: a pilot study. Biol Psychiatry 1996;40(11):1132–4.
Ben-Aryeh H , Jungerman T , Szargel R , Klein E , Laufer D . Salivary flow-rate and composition in schizophrenic patients on clozapine: subjective reports and laboratory data. Biol Psychiatry 1996;39(11):946–9.
Pretorius JL , Phillips M , Langley RW , Szabadi E , Bradshaw CM . Comparison of clozapine and haloperidol on some autonomic and psychomotor functions, and on serum prolactin concentration, in healthy subjects. Br J Clin Pharmacol 2001;52(3):322–6.
McCarthy RH , Terkelsen KG . Esophageal dysfunction in two patients after clozapine treatment. J Clin Psychopharmacol 1994;14(4):281–3.
Pearlman C . Clozapine, nocturnal sialorrhea, and choking. J Clin Psychopharmacol 1994;14(4):283.
Davydov L , Botts SR . Clozapine-induced hypersalivation. Ann Pharmacother 2000;34(5):662–5.
Safferman A , Lieberman JA , Kane JM , Szymanski S , Kinon B . Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991;17(2):247–61.
Boyce HW , Bakheet MR . Sialorrhea: a review of a vexing, often unrecognized sign of oropharyngeal and esophageal disease. J Clin Gastroenterol 2005;39(2):89–97.
Bristol-Myers Squibb , Otsuka America Pharmaceutical . Abilify (Aripiprazole) U.S. Full Prescribing Information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd.; 2008.
Praharaj SK , Jana AK , Sinha VK . Aripiprazole-induced sialorrhea. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(2):384–5.
Tuunainen A , Wahlbeck K , Gilbody SM . Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst Rev 2000;(2):CD000966.
Wahlbeck K , Cheine M , Essali MA . Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2000;(2):CD000059.
de Leon J , Odom-White A , Josiassen RC , Diaz FJ , Cooper TB , Simpson GM . Serum antimuscarinic activity during clozapine treatment. J Clin Psychopharmacol 2003;23(4):336–41.
Tollefson GD , Beasley CM , Jr, Tran PV , et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154(4):457–65.
Bagnall AM , Jones L , Ginnelly L , et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 2003;7(13):1–193.
Tran PV , Hamilton SH , Kuntz AJ , et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17(5):407–18.
Janssen-Ortho Inc . Invega (Paliperidone) Canadian Product Monograph. Toronto, Canada: Janssen-Ortho Inc.; 2009.
Oulis P , Masdrakis VG , Karakatsanis NA , Kouzoupis AV , Papadimitriou GN . Quetiapine-induced dose-dependent hypersalivation in mania. Clin Neuropharmacol 2009;32(1):56–7.
Allen S , Hoffer Z , Mathews M . Quetiapine-induced hypersalivation. Prim Care Companion J Clin Psychiatry 2007;9(3):233.
Pfizer Canada Inc . Zeldox (Ziprasidone hydrochloride) Canadian Product Monograph. Quebec, Canada: Pfizer Canada Inc.; 2007.
Beasley CM , Jr, Hamilton SH , Crawford AM , et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7(2):125–37.
Kane J , Honigfeld G , Singer J , Meltzer H . Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789–96.

Reference Title: References

Reference Type: reference-list

Warnock JK , Morris DW . Adverse cutaneous reactions to antipsychotics. Am J Clin Dermatol 2002;3(9):629–36.
Lange-Asschenfeldt C , Grohmann R , Lange-Asschenfeldt B , Engel RR , Ruther E , Cordes J . Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program. J Clin Psychiatry 2009;70(9):1258–65.
Harth Y , Rapoport M . Photosensitivity associated with antipsychotics, antidepressants and anxiolytics. Drug Saf 1996;14(4):252–9.
Kimyai-Asadi A , Harris JC , Nousari HC . Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999;60(10):714–25; quiz 726.
Gregoriou S , Karagiorga T , Stratigos A , Volonakis K , Kontochristopoulos G , Rigopoulos D . Photo-onycholysis caused by olanzapine and aripiprazole. J Clin Psychopharmacol 2008;28(2):219–20.
Mishra B , Praharaj SK , Prakash R , Sinha VK . Aripiprazole-induced acneiform eruption. Gen Hosp Psychiatry 2008;30(5):479–81.
Howanitz E , Pardo M , Losonczy M . Photosensitivity to clozapine. J Clin Psychiatry 1995;56(12):589.
Jaunkalns R , Shear NH , Sokoluk B , Gardner D , Claas F , Uetrecht JP . Antimyeloperoxidase antibodies and adverse reactions to clozapine. Lancet 1992;339(8809):1611–12.
Kleinen JM , Bouckaert F , Peuskens J . Clozapine-induced agranulocytosis and Sweet's syndrome in a 74-year-old female patient. A case study. Tijdschr Psychiatr 2008;50(2):119–23.
Mishra B , Sahoo S , Sarkar S , Akhtar S . Clozapine-induced angioneurotic edema. Gen Hosp Psychiatry 2007;29(1):78–80.
Bhatti MA , Zander J , Reeve E . Clozapine-induced pericarditis, pericardial tamponade, polyserositis, and rash. J Clin Psychiatry 2005;66(11):1490–1.
Christen S , Gueissaz F , Anex R , Zullino DF . Acute generalized exanthematous pustulosis induced by olanzapine. Acta Medica (Hradec Kralove) 2006;49(1):75–6.
Jhirwal OP , Parsad D , Basu D . Skin hyperpigmentation induced by olanzapine, a novel antipsychotic agent. Int J Dermatol 2004;43(10):778–9.
MacMorran WS , Krahn LE . Adverse cutaneous reactions to psychotropic drugs. Psychosomatics 1997;38(5):413–22.
Akkaya C , Sarandol A , Aydogan K , Kirli S . Urticaria and angio-oedema due to ziprasidone. J Psychopharmacol 2007;21(5):550–2.
Nobrega LPC , Baldacara L , Kumagai F , Freirias A , Tamai S , Sanches M . Drug eruptions associated with ziprasidone. Rev Psiquiatr Clin 2005;32(2):84–7.
Srebrnik A , Hes JP , Brenner S . Adverse cutaneous reactions to psychotropic drugs. Acta Derm Venereol Suppl (Stockh) 1991;158:1–12.
Chignell CF , Motten AG , Buettner GR . Photoinduced free radicals from chlorpromazine and related phenothiazines: relationship to phenothiazine-induced photosensitization. Environ Health Perspect 1985;64:103–10.
Eberlein-Konig B , Bindl A , Przybilla B . Phototoxic properties of neuroleptic drugs. Dermatology 1997;194(2):131–5.
Ban TA , Guy W , Wilson WH . Neuroleptic-induced skin pigmentation in chronic hospitalized schizophrenic patients. Can J Psychiatry 1985;30(6):406–8.
Greenfield JR , McGrath M , Kossard S , Charlesworth JA , Campbell LV . ANCA-positive vasculitis induced by thioridazine: confirmed by rechallenge. Br J Dermatol 2002;147(6):1265–7.

Reference Title: References

Reference Type: reference-list

Kane JM. Tardive dyskinesia. In Young RR , Joseph AB , eds., Movement Disorders in Neurology and Neuropsychiatry, 3rd edn. Malden, MA: Blackwell Science, Inc.; 1999.
Tarsy D . Akathisia . In Young RR , Joseph AB , eds., Movement Disorders in Neurology and Neuropsychiatry, 3rd edn. Malden, MA: Blackwell Science, Inc.; 1999.
Owens DG , Johnstone EC , Frith CD . Spontaneous involuntary disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry 1982;39(4):452–61.
American Psychiatric Association . Tardive Dyskinesia: a Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1992.
Jenner P , Marsden CD. Neuroleptic-induced tardive dyskinesia. Acta Psychiatr Belg 1987;87(5):566–98.
Correll CU , Leucht S , Kane JM . Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161(3):414–25.
Correll CU , Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21(2):151–6.
Gardos G , Cole JO. Severe tardive dyskinesia. In Young RR , Joseph AB , eds., Movement Disorders in Neurology and Neuropsychiatry, 3rd edn. Malden, MA: Blackwell Science, Inc.; 1999.
Miller del D , Caroff SN , Davis SM , et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008;193(4):279–88.
Bristol-Myers Squibb , Otsuka America Pharmaceutical . Abilify (Aripiprazole) U.S. Full Prescribing Information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd.; 2008.
Anonymous . Aripiprazole improves neuroleptic-associated tardive dyskinesia, but it does not meliorate psychotic symptoms. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(5):1342–3.
Caykoylu A , Ekinci O , Yilmaz E . Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(3):571–2.
Duggal HS. Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiatry 2003;48(11):771–2.
Grant MJ , Baldessarini RJ . Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole. Ann Pharmacother 2005;39(11):1953.
Lykouras L , Rizos E , Gournellis R . Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(7):1535–6.
Rajarethinam R , Dziuba J , Manji S , Pizzuti A , Lachover L , Keshavan M . Use of aripiprazole in tardive dyskinesia: an open label study of six cases. World J Biol Psychiatry 2009;10:416–19.
Sharma A , Ramaswamy S , Dewan VK . Resolution of ziprasidone-related tardive dyskinesia with a switch to aripiprazole. Prim Care Companion J Clin Psychiatry 2005;7(1):36.
Witschy JK , Winter AS. Improvement in tardive dyskinesia with aripiprazole use. Can J Psychiatry 2005;50(3):188.
Kantrowitz JT , Srihari VH , Tek C . Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot. J Clin Psychopharmacol 2007;27(5):525–6.
Abbasian C , Power P . A case of aripiprazole and tardive dyskinesia. J Psychopharmacol 2009;23(2):214–15.
Evcimen YA , Evcimen H , Holland J . Aripiprazole-induced tardive dyskinesia: the role of tamoxifen. Am J Psychiatry 2007;164(9):1436–7.
Wang LJ , Ree SC , Chen CK . Courses of aripiprazole-associated tardive dyskinesia: report of two cases. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(4):743–4.
Lungu C , Aia PG , Shih LC , Esper CD , Factor SA , Tarsy D . Tardive dyskinesia due to aripiprazole: report of 2 cases. J Clin Psychopharmacol 2009;29(2):185–6.
Tamminga CA , Thaker GK , Moran M , Kakigi T , Gao XM. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994;55 Suppl. B:102–6.
Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry 2004;65 Suppl. 9:21–4.
Tollefson GD , Birkett MA , Kiesler GM , Wood AJ , Lilly Resistant Schizophrenia Study Group . Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 2001;49(1):52–63.
Spivak B , Mester R , Abesgaus J , et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997;58(7):318–22.
Novick D , Haro JM , Perrin E , Suarez D , Texeira JM . Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol 2009;19(8):542–50.
Kinon B , Jeste DV , Stauffer V , et al. Olanzapine improves tardive dyskinesia in patients with schizophrenia (abstract). In 155th Annual Meeting of the American Psychiatric Association, May 18–23, 2002; Philadelphia, PA.
Jeste DV , Okamoto A , Napolitano J , Kane JM , Martinez RA . Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000;157(7):1150–5.
Oosthuizen PP , Emsley RA , Maritz JS , Turner JA , Keyter N . Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003;64(9):1075–80.
Adityanjee , Aderibigbe YA , Jampala VC , Mathews T . The current status of tardive dystonia. Biol Psychiatry 1999;45(6):715–30.

Reference Title: References

Reference Type: reference-list

Pollack MH , Reiter S , Hammerness P . Genitourinary and sexual adverse effects of psychotropic medication. Int J Psychiatry Med 1992;22(4):305–27.
Berrios GE . Temporary urinary incontinence in the acute psychiatric patient without delirium or dementia. Br J Psychiatry 1986;149:224–7.
Tsakiris P , Oelke M , Michel MC . Drug-induced urinary incontinence. Drugs Aging 2008;25(7):541–9.
Lindesay J , Matthews R , Jagger C . Factors associated with antipsychotic drug use in residential care: changes between 1990 and 1997. Int J Geriatr Psychiatry 2003;18(6):511–19.
Ambrosini PJ , Nurnberg HG . Enuresis and incontinence occurring with neuroleptics. Am J Psychiatry 1980;137(10):1278–9.
Agarwal V . Urinary incontinence with risperidone. J Clin Psychiatry 2000;61(3):219.
Lieberman JA . Maximizing clozapine therapy: managing side effects. J Clin Psychiatry 1998;59 Suppl. 3:38–43.
English BA , Still DJ , Harper J , Saklad SR . Failure of tolterodine to treat clozapine-induced nocturnal enuresis. Ann Pharmacother 2001;35(7–8):867–9.
Vera PL , Miranda-Sousa A , Nadelhaft I . Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats. BMC Pharmacol 2001;1:4.
Fuller MA , Borovicka MC , Jaskiw GE , Simon MR , Kwon K , Konicki PE . Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. J Clin Psychiatry 1996;57(11):514–18.
Warner JP , Harvey CA , Barnes TR . Clozapine and urinary incontinence. Int Clin Psychopharmacol 1994;9(3):207–9.
Bristol-Myers Squibb, Otsuka America Pharmaceutical . Abilify (Aripiprazole) U.S. Full Prescribing Information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd.; 2008.
Novartis Pharmaceuticals Canada Inc . Clozaril (Clozapine) Canadian Prescribing Information. Dorval, QC: Novartis Pharmaceuticals Canada Inc.; 2007.
Lin CC , Bai YM , Chen JY , Lin CY , Lan TH . A retrospective study of clozapine and urinary incontinence in Chinese in-patients. Acta Psychiatr Scand 1999;100(2):158–61.
Mendhekar DN , Duggal HS . Clozapine-induced double incontinence. Indian J Med Sci 2007;61(12):665–6.
Lieberman JA , Stroup TS , McEvoy JP , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209–23.
Tollefson GD , Beasley CM, Jr , Tran PV , et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154(4):457–65.
Vernon LT , Fuller MA , Hattab H , Varnes KM . Olanzapine-induced urinary incontinence: treatment with ephedrine. J Clin Psychiatry 2000;61(8):601–2.
Sagar R , Varghese ST , Balhara YP . Olanzapine-induced double incontinence. Indian J Med Sci 2005;59(4):163–4.
Janssen-Ortho Inc . Invega (Paliperidone) Canadian Product Monograph. Toronto, Canada: Janssen-Ortho Inc.; 2009.
AstraZeneca Canada Inc . Seroquel XR (Quetiapine fumarate) Canadian Product Monograph. Mississauga, ON: AstraZeneca Canada Inc.; 2009.
Gardner DM , Baldessarini RJ , Waraich P . Modern antipsychotic drugs: a critical overview. CMAJ 2005;172(13):1703–11.
Janssen-Ortho Inc . Risperdal (Risperidone) Product Monograph. Toronto, Canada: Janssen-Ortho Inc.; 2008.
Vokas CS , Steele VM , Norris JI , Vernon LT , Brescan DW . Incidence of risperidone-induced incontinence [abstract]. Schizophr Res 1997;24(102):267.
Herguner S , Mukaddes NM . Risperidone-induced double incontinence. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(4):1085–6.
Pfizer Canada Inc . Zeldox (Ziprasidone hydrochloride) Canadian Product Monograph. Quebec, Canada: Pfizer Canada Inc.; 2007.
Nurnberg HG , Ambrosini PJ . Urinary incontinence in patients receiving neuroleptics. J Clin Psychiatry 1979;40(6):271–4.
Alvi T , Reza H . Neuroleptic induced incontinence – case report. J Pak Med Assoc 1997;47(7):195–6.
Shaikh A . Urinary incontinence during treatment with depot phenothiazines. Br Med J 1978;1(6128):1698.
Shapiro AK . Pimozide-induced enuresis. Am J Psychiatry 1981;138(1):123–4.
Shenoy RS . Nocturnal enuresis caused by psychotropic drugs. Am J Psychiatry 1980;137(6):739–40.
Crittenden FM, Jr . Thioridazine incontinence. JAMA 1972;219(2):217.
Van Putten T , Malkin MD , Weiss MS . Phenothiazine-induced stress incontinence. J Urol 1973;109(4):625–6.
Kiruluta HG , Andrews K . Urinary incontinence secondary to drugs. Urology 1983;22(1):88–90.

Reference Title: References

Reference Type: reference-list

Bates SM , Ginsberg JS . Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med 2004;351(3):268–77.
Raskob GE , Hull DH , Pineo GF . Venous thrombosis. In Lichtman MA , Kipps TJ , Kaushansky K , Beutler E , Seligsohn U , Prchal JT , eds., Williams Hematology, 7th edn. New York: McGraw-Hill, Medical Publishing Division; 2006.
Goldhaber SZ . Pulmonary embolism. Lancet 2004;363(9417):1295–305.
Motykie GD , Zebala LP , Caprini JA , et al. A guide to venous thromboembolism risk factor assessment. J Thromb Thrombolysis 2000;9(3):253–62.
Rosendaal FR . Risk factors for venous thrombotic disease. Thromb Haemost 1999;82(2):610–19.
Douketis JD . Prognosis in pulmonary embolism. Curr Opin Pulm Med 2001;7(5):354–9.
Hagg S , Spigset O . Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs 2002;16(11):765–76.
Allison DB , Mentore JL , Heo M , et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156(11):1686–96.
Greaves M . Antiphospholipid antibodies and thrombosis. Lancet 1999;353(9161):1348–53.
Schwartz M , Rochas M , Weller B , et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry 1998;59(1):20–3.
Lacut K , Le Gal G , Couturaud F , et al. Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case–control study. Fundam Clin Pharmacol 2007;21(6):643–50.
Turpie AGG . Cardiovascular disorders: venous thromboembolism. In Gray J , ed., Therapeutic Choices, 5th edn. Ottawa, ON: Canadian Pharmacists Association; 2007.
Hagg S , Tatting P , Spigset O . Olanzapine and venous thromboembolism. Int Clin Psychopharmacol 2003;18(5):299–300.
Bristol-Myers Squibb, Otsuka America Pharmaceutical . Abilify (Aripiprazole) U.S. Full Prescribing Information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd.; 2008.
Hagg S , Spigset O , Soderstrom TG . Association of venous thromboembolism and clozapine. Lancet 2000;355(9210):1155–6.
Paciullo CA . Evaluating the association between clozapine and venous thromboembolism. Am J Health Syst Pharm 2008;65(19):1825–9.
Knudson JF , Kortepeter C , Dubitsky GM , Ahmad SR , Chen M . Antipsychotic drugs and venous thromboembolism. Lancet 2000;356(9225):252–3.
Waage IM , Gedde-Dahl A . Pulmonary embolism possibly associated with olanzapine treatment. BMJ 2003;327(7428):1384.
Maly R , Masopust J , Hosak L , Urban A . Four cases of venous thromboembolism associated with olanzapine. Psychiatry Clin Neurosci 2009;63(1):116–18.
Borras L , Eytan A , de Timary P , Constant EL , Huguelet P , Hermans C . Pulmonary thromboembolism associated with olanzapine and risperidone. J Emerg Med 2008;35(2):159–61.
del Conde I , Goldhaber SZ . Pulmonary embolism associated with olanzapine. Thromb Haemost 2006;96(5):690–1.
Toki S , Morinobu S , Yoshino A , Yamawaki S . A case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics. J Clin Psychiatry 2004;65(11):1576–7.
Janssen-Ortho Inc . Invega (Paliperidone) Canadian Product Monograph. Toronto, Canada: Janssen-Ortho Inc.; 2009.
Kamijo Y , Soma K , Nagai T , Kurihara K , Ohwada T . Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines. Circ J 2003;67(1):46–8.
Zink M , Knopf U , Argiriou S , Kuwilsky A . A case of pulmonary thromboembolism and rhabdomyolysis during therapy with mirtazapine and risperidone. J Clin Psychiatry 2006;67(5):835.
Pfizer Canada Inc . Zeldox (Ziprasidone hydrochloride) Canadian Product Monograph. Quebec, Canada: Pfizer Canada Inc.; 2007.
Zornberg GL , Jick H . Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case–control study. Lancet 2000;356(9237):1219–23.
Parkin L , Skegg DC , Herbison GP , Paul C . Psychotropic drugs and fatal pulmonary embolism. Pharmacoepidemiol Drug Saf 2003;12(8):647–52.

Reference Title: References

Reference Type: reference-list

Buckley NA , Sanders P . Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 2000;23(3):215–28.
Fayek M , Kingsbury SJ , Zada J , Simpson GM . Cardiac effects of antipsychotic medications. Psychiatr Serv 2001;52(5):607–9.
Baldessarini RJ , Tarazi FI . Pharmacotherapy of psychosis and mania. In Brunton LL , Lazo JS , Parker K , eds., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn. New York: McGraw-Hill; 2006.
Newman SC , Bland RC . Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991;36(4):239–45.
Waddington JL , Youssef HA , Kinsella A . Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998;173:325–9.
Seeman MV . An outcome measure in schizophrenia: mortality. Can J Psychiatry 2007;52(1):55–60.
Haddad PM , Anderson IM . Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62(11):1649–71.
Ray WA , Chung CP , Murray KT , Hall K , Stein CM . Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360(3):225–35.
Ray WA , Meredith S , Thapa PB , Meador KG , Hall K , Murray KT . Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58(12):1161–7.
Straus SM , Bleumink GS , Dieleman JP , et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 2004;164(12):1293–7.
Huikuri HV , Makikallio T , Airaksinen KE , Mitrani R , Castellanos A , Myerburg RJ . Measurement of heart rate variability: a clinical tool or a research toy? J Am Coll Cardiol 1999;34(7):1878–83.
Agelink MW , Malessa R , Kamcili E , et al. Cardiovascular autonomic reactivity in schizophrenics under neuroleptic treatment: a potential predictor of short-term outcome? Neuropsychobiology 1998;38(1):19–24.
Zahn TP , Pickar D . Autonomic effects of clozapine in schizophrenia: comparison with placebo and fluphenazine. Biol Psychiatry 1993;34(1–2):3–12.
Silke B , Campbell C , King DJ . The potential cardiotoxicity of antipsychotic drugs as assessed by heart rate variability. J Psychopharmacol 2002;16(4):355–60.
Wang YC , Yang CC , Bai YM , Kuo TB . Heart rate variability in schizophrenic patients switched from typical antipsychotic agents to amisulpride and olanzapine. 3-Month follow-up. Neuropsychobiology 2008;57(4):200–5.
Stein KM . Noninvasive risk stratification for sudden death: signal-averaged electrocardiography, nonsustained ventricular tachycardia, heart rate variability, baroreflex sensitivity, and QRS duration. Prog Cardiovasc Dis 2008;51(2):106–17.
Silver H , Kogan H , Zlotogorski D . Postural hypotension in chronically medicated schizophrenics. J Clin Psychiatry 1990;51(11):459–62.
Ennis LM , Parker RM . Paradoxical hypertension associated with clozapine. Med J Aust 1997;166(5):278.
Coulter D . Atypical antipsychotics may cause hypotension. Prescriber Update 2003;24(1):4–5.
Vassallo SU , Delany KA . Thermoregulatory principles. In Wonsiewicz MJ , Edmonson KG , Boyle PJ , eds., Goldfrank's Toxicologic Emergencies, 8th edn. New York: McGraw Hill; 2006.
Martinez M , Devenport L , Saussy J , Martinez J . Drug-associated heat stroke. South Med J 2002;95(8):799–802.
van Marum RJ , Wegewijs MA , Loonen AJ , Beers E . Hypothermia following antipsychotic drug use. Eur J Clin Pharmacol 2007;63(6):627–31.
Hermesh H , Shiloh R , Epstein Y , Manaim H , Weizman A , Munitz H . Heat intolerance in patients with chronic schizophrenia maintained with antipsychotic drugs. Am J Psychiatry 2000;157(8):1327–9.
Bristol-Myers Squibb Canada . Abilify (Aripiprazole) Product Monograph. Montreal, Canada: Bristol-Myers Squibb Canada; 2009.
Novartis Pharmaceuticals Canada Inc . Clozaril (Clozapine) Canadian Prescribing Information. Dorval, QC: Novartis Pharmaceuticals Canada Inc.; 2007.
Bauer D , Gaertner HJ . Effects of neuroleptics on liver function, the hematopoietic system, blood pressure and temperature regulation. Comparison of clozapine, perazine and haloperidol by evaluating medical records. Pharmacopsychiatria 1983;16(1):23–9.
Layland JJ , Liew D , Prior DL . Clozapine-induced cardiotoxicity: a clinical update. Med J Aust 2009;190(4):190–2.
Haas SJ , Hill R , Krum H , et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993–2003. Drug Saf 2007;30(1):47–57.
Lilly . Zyprexa (Olanzapine) Product Monograph. Toronto, Canada: Lilly; 2008.
Janssen-Ortho Inc . Invega (Paliperidone) Canadian Product Monograph. Toronto, Canada: Janssen-Ortho Inc.; 2009.
AstraZeneca Canada Inc . Seroquel XR (Quetiapine fumarate) Canadian Product Monograph. Mississauga, ON: AstraZeneca Canada Inc.; 2009.
AstraZeneca Canada Inc . Seroquel (Quetiapine) Product Monograph. Toronto, Canada: AstraZeneca Canada Inc.; 2008.
Janssen-Ortho Inc . Risperdal (Risperidone) Product Monograph. Toronto, Canada: Janssen-Ortho Inc.; 2008.
Janssen-Ortho Inc . Risperdal Consta (Risperidone) Product Monograph. Toronto, Canada: Janssen-Ortho Inc.; 2009.
Pfizer Canada Inc . Zeldox (Ziprasidone hydrochloride) Canadian Product Monograph. Quebec, Canada: Pfizer Canada Inc.; 2007.